Although there was a limited sample size, the results of our study suggest that administration of next-generation central nervous system–penetrant TKIs as subsequent treatment is associated with longer survival and may contribute more to OS than BRT in EGFR-mutant NSCLC with brain metastases. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.